The benzazepine SCH 23390 increases plasma levels of cortisol in the conscious dog

[1]  H. Schoemaker,et al.  5HT-receptor antagonist properties of SCH 23390 in vascular smooth muscle and brain. , 1984, European journal of pharmacology.

[2]  A. Barnett,et al.  SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems. , 1983, The Journal of pharmacology and experimental therapeutics.

[3]  J. Hyttel.  SCH 23390 - the first selective dopamine D-1 antagonist. , 1983, European journal of pharmacology.

[4]  M. Goiny,et al.  Effects of apomorphine and haloperidol on plasma cortisol levels in conscious dogs. , 1981, Acta Physiologica Scandinavica.

[5]  S. Peroutka,et al.  Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic, and histamine receptors to clinical potency. , 1980, The American journal of psychiatry.

[6]  J. Buckingham.  Corticotrophin releasing factor. , 1979, Pharmacological reviews.

[7]  D. Wied.  CHLORPROMAZINE AND ENDOCRINE FUNCTION , 1967 .

[8]  J. Larsen,et al.  Receptor-binding profiles of neuroleptics. , 1985, Psychopharmacology. Supplementum.

[9]  P. Seeman.  Brain dopamine receptors in schizophrenia and tardive dyskinesia. , 1985, Psychopharmacology. Supplementum.

[10]  U. Ungerstedt,et al.  Functional classification of different dopamine receptors. , 1985, Psychopharmacology. Supplementum.

[11]  P. Janssen.  5-HT2 receptor blockade to study serotonin-induced pathology , 1983 .

[12]  P. Giraud,et al.  Influence of haloperidol on ACTH and beta-endorphin secretion in the rat. , 1980, European Journal of Pharmacology.

[13]  B. Marks,et al.  Reserpine- and chlorpromazine-induced changes in hypothalamo-hypophyseal-adrenal system in rats in the presence and absence of hypothermia. , 1969, The Journal of pharmacology and experimental therapeutics.